Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $32.00 Price Target at Stifel Nicolaus

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its target price trimmed by Stifel Nicolaus from $36.00 to $32.00 in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on ZNTL. HC Wainwright reissued a buy rating and issued a $46.00 target price on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Wedbush raised their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a neutral rating in a report on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $37.14.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL opened at $12.43 on Wednesday. The company has a market capitalization of $882.65 million, a price-to-earnings ratio of -2.74 and a beta of 1.82. The stock has a 50-day moving average of $13.70 and a 200 day moving average of $13.43. Zentalis Pharmaceuticals has a one year low of $9.56 and a one year high of $31.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $35.00 million. During the same period in the previous year, the firm earned ($1.07) earnings per share. On average, equities analysts predict that Zentalis Pharmaceuticals will post -3.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Melissa B. Epperly sold 2,573 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the sale, the chief financial officer now directly owns 451,449 shares in the company, valued at $5,164,576.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Eventide Asset Management LLC raised its position in Zentalis Pharmaceuticals by 47.9% during the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after purchasing an additional 3,745,936 shares during the period. Vanguard Group Inc. raised its position in Zentalis Pharmaceuticals by 6.2% during the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock valued at $105,047,000 after purchasing an additional 307,490 shares during the period. Federated Hermes Inc. raised its position in Zentalis Pharmaceuticals by 10.9% during the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after purchasing an additional 212,872 shares during the period. Decheng Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $31,809,000. Finally, Wellington Management Group LLP raised its position in Zentalis Pharmaceuticals by 0.5% during the third quarter. Wellington Management Group LLP now owns 1,917,105 shares of the company’s stock valued at $38,457,000 after purchasing an additional 8,661 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.